Komal Jhaveri, MD, FACP, on Advanced Breast Cancer: Adding a PI3K Inhibitor to the Treatment Mix

Posted: Wednesday, September 11, 2024

Komal Jhaveri MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses the findings of the phase Ill INAVO120 trial in PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer and how effective it can be to add a PI3K inhibitor such as inavolisib to the combination of the CDK4/6 inhibitor palbociclib and the hormone therapy fulvestrant.

---